BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36161271)

  • 1. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    Mailliez A; D'Hondt V; Lusque A; Caron O; Cabel L; Goncalves A; Debled M; Gladieff L; Ferrero JM; Petit T; Mouret-Reynier MA; Eymard JC; Levy C; Uwer L; Leheurteur M; Desmoulins I; Bachelot T; Frenel JS; de la Motte Rouge T; Simon G; Jacot W; Delaloge S
    Int J Cancer; 2023 Mar; 152(5):921-931. PubMed ID: 36161271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
    Frenel JS; Lusque A; Delaloge S; Ferrero JM; Bachelot T; Desmoulins I; Levy C; Eymard JC; Gonçalves A; Patsouris A; Reynier MAM; Thery MJ; Petit T; Cabel L; Uwer L; Debled M; Chevrot M; Mailliez A; Jacot W; de La Motte Rouge T
    Br J Cancer; 2023 Jun; 128(11):2072-2080. PubMed ID: 37012318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
    Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
    Jacot W; Lusque A; Vicier C; Mailliez A; de La Motte Rouge T; Cabel L; Levy C; Patsouris A; Desmoulins I; Uwer L; Thery JC; Robain M; Caron O; Tredan O; Filleron T; Frenel JS; Delaloge S
    Br J Cancer; 2022 Nov; 127(11):1963-1973. PubMed ID: 36207609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    Collins JM; Nordstrom BL; McLaurin KK; Dalvi TB; McCutcheon SC; Bennett JC; Murphy BR; Singhal PK; McCrea C; Shinde R; Briceno JM
    Oncol Ther; 2021 Dec; 9(2):575-589. PubMed ID: 34308518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
    Grinda T; Antoine A; Jacot W; Cottu PH; de la Motte Rouge T; Frenel JS; Mailliez A; Dalenc F; Goncalves A; Clatot F; Mouret Reynier MA; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Arnedos M; Chevrot M; Courtinard C; Tredan O; Brain E; Pérol D; Pistilli B; Delaloge S
    Eur J Cancer; 2023 Aug; 189():112935. PubMed ID: 37385070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
    Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
    Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
    Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
    Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status.
    Hage AM; Gebert P; Blohmer JU; Hedayati E; Speiser D; Karsten MM
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
    Savill KMZ; Ivanova J; Asgarisabet P; Falkenstein A; Balanean A; Niyazov A; Ryan JC; Kish J; Gajra A; Mahtani RL
    Oncologist; 2023 May; 28(5):414-424. PubMed ID: 36952230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
    Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
    BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.
    Annonay M; Gauquelin L; Geiss R; Ung M; Cristol-Dalstein L; Mouret-Reynier MA; Goncalves A; Abadie-Lacourtoisie S; Francois E; Perrin C; Le Fel J; Lorgis V; Servent V; Uwer L; Jouannaud C; Leheurteur M; Joly F; Campion L; Courtinard C; Villacroux O; Petit T; Soubeyran P; Terret C; Bellera C; Brain E; Delaloge S
    Breast; 2021 Dec; 60():138-146. PubMed ID: 34624756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
    Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
    Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Dalenc F; Lusque A; De La Motte Rouge T; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; Levy C; Uwer L; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Frenel JS; Petit T; Chevrot M; Bachelot T; Guiu S
    Eur J Cancer; 2022 Mar; 164():70-79. PubMed ID: 35176614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of the management and prognosis of young women (⩽40 years) with
    Mallet A; Lusque A; Levy C; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; De La Motte Rouge T; Faure C; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Cottu P; Dalenc F; Petit T; Payen O; Uwer L; Guiu S; Frenel JS
    Ther Adv Med Oncol; 2022; 14():17588359211070362. PubMed ID: 35082924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.